extract: 2024-11-01-aspe-medicare-anti-obesity-medication-coverage
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
11a55c597e
commit
d2319195b6
6 changed files with 62 additions and 1 deletions
|
|
@ -23,6 +23,12 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
|
|||
|
||||
Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-15*
|
||||
|
||||
When eligibility is restricted to Medicare beneficiaries with comorbidities (CVD history, heart failure, CKD, prediabetes) rather than BMI alone, approximately 10% of Medicare beneficiaries become eligible. This comorbidity-gated approach changes the cost-benefit calculation: ASPE estimates annual Part D cost increases of $3.1-6.1 billion but projects net savings of $715M over 10 years through avoided cardiovascular events and kidney disease progression. The divergence from CBO's $35B cost estimate reveals that the 'inflationary through 2035' thesis depends heavily on which methodology and eligibility criteria are used.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -39,6 +39,12 @@ The GLP-1 case is particularly stark because the clinical evidence is robust (ca
|
|||
|
||||
The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-15*
|
||||
|
||||
The GLP-1 coverage debate provides a quantified example: CBO's $35B cost estimate vs. ASPE's $715M savings calculation represents a $35.7 billion methodological divergence on a single drug class. ASPE analysis shows broad semaglutide access would avoid 38,950 CV events and 6,180 deaths over 10 years, but CBO scoring rules structurally undercount these downstream savings because they apply conservative uptake assumptions and don't fully credit avoided hospitalizations within the budget window.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
|
|||
- Nature Medicine: additive benefits with SGLT2 inhibitors
|
||||
- First GLP-1 to receive FDA indication for CKD in T2D patients
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-15*
|
||||
|
||||
ASPE's clinical economics model explicitly accounts for multi-organ protection: 38,950 cardiovascular events avoided, 6,180 deaths prevented, and kidney disease progression reduction all contribute to the net savings calculation. The comorbidity-gated eligibility criteria (CVD history, heart failure, CKD, prediabetes) target exactly the populations where multi-organ protection creates compounding value, which is why clinical economics shows savings while budget scoring shows costs.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
- FDA indication expansion to T2D patients with CKD (2024)
|
||||
- Dialysis cost benchmark: $90K+/year per patient
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-15*
|
||||
|
||||
ASPE's analysis of broad semaglutide access includes kidney disease progression as a major component of the net savings calculation. The comorbidity-based eligibility criteria specifically include CKD patients, and the $715M net savings figure incorporates avoided dialysis costs as part of the downstream benefit calculation that CBO methodology undercounts.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "federal-budget-scoring-creates-35-billion-divergence-from-clinical-economics-on-glp-1-coverage-because-cbo-methodology-excludes-downstream-savings.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"federal-budget-scoring-creates-35-billion-divergence-from-clinical-economics-on-glp-1-coverage-because-cbo-methodology-excludes-downstream-savings.md:set_created:2026-03-15"
|
||||
],
|
||||
"rejections": [
|
||||
"federal-budget-scoring-creates-35-billion-divergence-from-clinical-economics-on-glp-1-coverage-because-cbo-methodology-excludes-downstream-savings.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-15"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2024-11-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: policy
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-15
|
||||
enrichments_applied: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -45,3 +49,12 @@ WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how preve
|
|||
EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers
|
||||
|
||||
flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- CBO estimates Medicare coverage of anti-obesity medications would increase federal spending by $35 billion over 2026-2034
|
||||
- ASPE estimates net savings of $715 million over 10 years (range: $412M to $1.04B) from the same policy
|
||||
- Broad semaglutide access would avoid 38,950 cardiovascular events and 6,180 deaths over 10 years according to ASPE
|
||||
- Annual Part D cost increase from Medicare GLP-1 coverage estimated at $3.1-6.1 billion
|
||||
- Approximately 10% of Medicare beneficiaries would be eligible under comorbidity-based criteria (CVD history, heart failure, CKD, prediabetes)
|
||||
- ASPE is the research arm of HHS; CBO is Congress's nonpartisan scorekeeper
|
||||
|
|
|
|||
Loading…
Reference in a new issue